The BCG Shortage.
作者信息
Messing Edward M
机构信息
University of Rochester Medical Center, Rochester, NY, USA.
出版信息
Bladder Cancer. 2017 Jul 27;3(3):227-228. doi: 10.3233/BLC-179018.
Abstract
摘要
相似文献
1
The BCG Shortage.卡介苗短缺
Bladder Cancer. 2017 Jul 27;3(3):227-228. doi: 10.3233/BLC-179018.
2
The impact of Bacille Calmette-Guérin shortage on immunisation practice and policies in Europe - A Paediatric Tuberculosis Network European Trials Group (ptbnet) survey.卡介苗短缺对欧洲免疫接种实践及政策的影响——一项欧洲儿科结核病网络试验组（ptbnet）调查
Tuberculosis (Edinb). 2016 Dec;101:125-129. doi: 10.1016/j.tube.2016.08.005. Epub 2016 Aug 31.
3
Comparison of pellicle and shake flask-grown BCG strains by quality control assays and protection studies.通过质量控制检测和保护研究对薄膜培养和摇瓶培养的卡介苗菌株进行比较。
Tuberculosis (Edinb). 2019 Jan;114:47-53. doi: 10.1016/j.tube.2018.10.013. Epub 2018 Nov 2.
4
The Moreau Strain of Bacillus Calmette-Guerin (BCG) for High-Risk Non-Muscle Invasive Bladder Cancer: An Alternative during Worldwide BCG Shortage?用于高危非肌层浸润性膀胱癌的卡介苗（BCG）莫罗菌株：在全球卡介苗短缺期间的一种替代选择？
Urol Int. 2016;96(1):46-50. doi: 10.1159/000440701. Epub 2015 Nov 11.
5
Manufacturing and the Market: Rationalizing the Shortage of Bacillus Calmette-Guérin.生产与市场：合理解决卡介苗短缺问题。
Eur Urol Focus. 2018 Jul;4(4):481-484. doi: 10.1016/j.euf.2018.06.018. Epub 2018 Jul 11.
6
Alternative Therapies to Calmette-Guérin Shortage for Nonmuscle Invasive Bladder Cancer in Brazil and Other Underdeveloped Countries: Management Considerations.巴西及其他不发达国家非肌肉浸润性膀胱癌卡介苗短缺的替代疗法：管理考量
J Glob Oncol. 2019 Aug;5:1-9. doi: 10.1200/JGO.19.00112.
7
BCG shortage in Europe.欧洲卡介苗短缺。
Prev Med. 2013 Aug;57(2):146. doi: 10.1016/j.ypmed.2013.04.019. Epub 2013 May 4.
8
[Endovesical treatment as an alternative to BCG for intermediate or high-risk NMI bladder cancer].[膀胱内治疗作为中高危非肌层浸润性膀胱癌卡介苗治疗的替代方案]
Urologia. 2013;80 Suppl 21:24-6. doi: 10.5301/RU.2013.10860. Epub 2013 Mar 22.
9
The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer.卡介苗TICE和卡介苗诺康在2099例T1G3非肌层浸润性膀胱癌患者队列中的疗效。
Urol Oncol. 2016 Nov;34(11):484.e19-484.e25. doi: 10.1016/j.urolonc.2016.05.033. Epub 2016 Sep 14.
10
[BCG and bladder cancer: Past, present and future.].[卡介苗与膀胱癌：过去、现在与未来。]
Arch Esp Urol. 2018 May;71(4):332-341.
引用本文的文献
1
cJun-N-terminal kinase activity and mitosis perturbation drive the 2-methoxyestradiol-mediated enhancement of viral oncolysis by Epizootic Hemorrhagic Disease Virus-Tel Aviv University.cJun氨基末端激酶活性和有丝分裂扰动驱动2-甲氧基雌二醇介导的流行性出血病病毒-特拉维夫大学对病毒溶瘤作用的增强。
Sci Rep. 2025 Jul 9;15(1):24624. doi: 10.1038/s41598-025-08687-8.
2
Revitalizing Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches.恢复卡介苗对膀胱癌的免疫治疗：纳米技术与生物工程方法
Pharmaceutics. 2024 Aug 15;16(8):1067. doi: 10.3390/pharmaceutics16081067.
3
A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette-Guérin and Immune Checkpoint Inhibitors.一种非肌肉浸润性膀胱癌的多基因标志物可识别对包括卡介苗和免疫检查点抑制剂在内的免疫疗法有反应的患者。
Int J Mol Sci. 2024 Mar 28;25(7):3800. doi: 10.3390/ijms25073800.
4
Redox System and Oxidative Stress-Targeted Therapeutic Approaches in Bladder Cancer.膀胱癌中的氧化还原系统与氧化应激靶向治疗方法
Antioxidants (Basel). 2024 Feb 26;13(3):287. doi: 10.3390/antiox13030287.
5
Efficacy and tolerability of bacillus Calmette-Guérin strain Russia for the treatment of non-muscle-invasive bladder cancer Analysis of a prospective registry.俄罗斯卡介苗菌株治疗非肌层浸润性膀胱癌的疗效和耐受性：一项前瞻性登记研究分析
Can Urol Assoc J. 2024 Jul;18(7):E233-E239. doi: 10.5489/cuaj.8552.
6
Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma.序贯腔内吉西他滨和多西他赛治疗临床非浸润性高级别上尿路尿路上皮癌。
Urol Oncol. 2024 Jan;42(1):20.e9-20.e15. doi: 10.1016/j.urolonc.2023.08.013. Epub 2023 Oct 5.
7
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.膀胱癌的定义、终点和临床试验设计：癌症免疫治疗学会和国际膀胱癌协会的建议。
J Clin Oncol. 2023 Dec 10;41(35):5437-5447. doi: 10.1200/JCO.23.00307. Epub 2023 Oct 4.
8
Instrumental dead space and proximal working channel connector design in flexible ureteroscopy: a new concept.软性输尿管镜检查中的器械死腔与近端工作通道连接器设计：一种新概念
Ther Adv Urol. 2023 Jun 24;15:17562872231179332. doi: 10.1177/17562872231179332. eCollection 2023 Jan-Dec.
9
Efficacy of recombinant Bacillus Calmette-Guérin containing dltA in three-dimensional bio-printed bladder cancer-on-a-chip and orthotopic mouse model.含 dltA 的重组卡介苗在三维生物打印膀胱癌芯片和原位小鼠模型中的疗效。
Investig Clin Urol. 2023 May;64(3):296-305. doi: 10.4111/icu.20220293.
10
Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the Bacillus Calmette-Guerin Drug Shortage.卡介苗药物短缺期间全州非肌肉浸润性膀胱癌膀胱内治疗率的变化。
Urology. 2023 Jul;177:74-80. doi: 10.1016/j.urology.2023.02.044. Epub 2023 Mar 25.
本文引用的文献
1
Ensuring Access to Injectable Generic Drugs - The Case of Intravesical BCG for Bladder Cancer.确保可获得注射用仿制药——以用于膀胱癌的膀胱内卡介苗为例。
N Engl J Med. 2017 Apr 13;376(15):1401-1403. doi: 10.1056/NEJMp1615697.
2
Association Between US Norepinephrine Shortage and Mortality Among Patients With Septic Shock.美国去甲肾上腺素短缺与脓毒性休克患者死亡率之间的关联。
JAMA. 2017 Apr 11;317(14):1433-1442. doi: 10.1001/jama.2017.2841.
3
Response to "Drug shortages and the burden of access to care: a critical issue affecting patients with cancer".对《药品短缺与医疗服务可及性负担：影响癌症患者的关键问题》的回应
Clin J Oncol Nurs. 2014 Apr;18(2):143-5.
4
Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.原有的卡介苗特异性 T 细胞可改善膀胱癌的膀胱内免疫治疗。
Sci Transl Med. 2012 Jun 6;4(137):137ra72. doi: 10.1126/scitranslmed.3003586.
5
The shortage of essential chemotherapy drugs in the United States.美国必需化疗药物的短缺。
N Engl J Med. 2011 Nov 3;365(18):1653-5. doi: 10.1056/NEJMp1109772. Epub 2011 Oct 31.
6
The burden of bladder cancer in men and women: analysis of the years of life lost.男性和女性膀胱癌的负担：生命损失年的分析。
BJU Int. 2012 Jan;109(1):57-62. doi: 10.1111/j.1464-410X.2011.10318.x. Epub 2011 Aug 23.
Zotero 插件